Glucolón (Glibenclamide)

Glucolón is used in clinical practice to help control hyperglycemia in patients with type 2 diabetes mellitus.

• As an adjunct to diet and exercise, it lowers elevated blood glucose levels.
• It may be used when metformin alone does not achieve target glycemic control.
• It is appropriate for adult patients whose pancreatic β‑cell function is still present.
• It can be part of a combination regimen with other oral antidiabetic agents, provided dosing is individualized.
• It may be considered for patients who prefer a once‑daily oral therapy over injectable options.
• It is not indicated for type 1 diabetes or for diabetic ketoacidosis.

Glucolón, like other sulfonylureas, can cause a range of adverse effects that vary in frequency and severity. These effects are reported in clinical studies and post‑marketing surveillance, and patients should be monitored regularly.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Mild fatigue or weakness.
• Increased urination or thirst, reflecting changes in glucose control.

Serious

• Severe hypoglycemia that may lead to loss of consciousness or seizures.
• Allergic reactions such as skin rash, itching, or swelling that could progress to anaphylaxis.
• Liver enzyme elevations indicating possible hepatic injury.
• Blood cell abnormalities such as leukopenia or thrombocytopenia.

When prescribing Glucolón, clinicians should consider several precautionary measures to minimize risks and ensure safe use.

• Assess renal and hepatic function before initiating therapy, as impairment can affect drug clearance.
• Verify that the patient has sufficient endogenous insulin production; sulfonylureas are ineffective in absolute insulin deficiency.
• Caution patients about the risk of hypoglycemia and advise regular meal patterns.
• Adjust dose or avoid use in elderly patients who may be more susceptible to adverse effects.
• Review concomitant medications that may potentiate hypoglycemia, such as other antidiabetics or beta‑blockers.
• Discontinue Glucolón during pregnancy or breastfeeding unless benefits outweigh potential risks.

Glucolón may interact with other medicines, altering its glucose‑lowering effect or increasing the likelihood of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole) that may raise glibenclamide plasma levels.
• Use with insulin therapy without dose adjustment, due to heightened hypoglycemia risk.

Use with caution

• Combination with beta‑blockers, which may mask hypoglycemia symptoms.
• Concomitant use of thiazide diuretics, which can affect blood glucose control.
• Use with oral anticoagulants, as glycemic fluctuations may influence INR stability.
• Caution when combined with antidepressants such as SSRIs, which may alter glucose metabolism.